A carregar...
Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays
Within the past few years, poly (ADP-ribose) polymerase inhibitors (PARPi) have been added to the standard of care for cancer patients, mainly for those exhibiting specific genomic alterations in the homologous recombination (HR) pathway. Until now, patients who are eligible to receive PARPi have be...
Na minha lista:
| Publicado no: | Br J Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8257604/ https://ncbi.nlm.nih.gov/pubmed/33767416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01295-z |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|